The MAHA Movement’s Worrisome Embrace of Ibogaine

The MAHA Movement is a nonprofit organization founded in 2020 in the United States to address the opioid crisis by promoting alternative addiction treatments. It advocates for the use of ibogaine, a psychoactive substance derived from the root bark of the African shrub Tabernanthe iboga, as a potential solution for opioid use disorder. The movement positions itself as a grassroots effort, aiming to influence public health policies and expand access to ibogaine therapy. It operates primarily through advocacy campaigns, educational initiatives, and partnerships with researchers and healthcare providers. The organization’s name, MAHA, stands for Movement Against Harmful Addiction, reflecting its mission to reduce harm associated with opioid addiction.

Ibogaine is a naturally occurring psychoactive compound that has gained attention for its potential to interrupt opioid addiction. Unlike traditional treatments such as methadone or buprenorphine, which are opioid-based and can themselves be addictive, ibogaine acts on multiple neurotransmitter systems in the brain, including those affected by opioids. Preliminary studies suggest it may reduce withdrawal symptoms and cravings by resetting neural pathways associated with addiction. However, ibogaine is not approved by the U.S. Food and Drug Administration (FDA) for medical use, and its safety profile remains uncertain. It carries significant risks, including potential heart complications and neurotoxicity, which have led to fatalities in uncontrolled settings.

The MAHA Movement has intensified its advocacy efforts in recent years, particularly in 2025, by lobbying for the legalization and regulated use of ibogaine in the United States. It argues that current addiction treatments are insufficient and that ibogaine could offer a breakthrough for individuals struggling with opioid use disorder. MAHA has partnered with researchers at institutions like the University of California, San Francisco, to study ibogaine’s efficacy and safety. The movement also promotes anecdotal success stories from individuals who claim ibogaine helped them overcome addiction, though these accounts are not scientifically validated. Its campaigns target policymakers, healthcare professionals, and the public to build support for broader acceptance of the treatment.

Despite MAHA’s enthusiasm, the scientific and medical communities remain cautious about ibogaine due to limited clinical evidence and significant safety concerns. The FDA has not approved ibogaine for any medical use, and its use outside of controlled clinical trials is considered experimental. A 2023 review published in the Journal of Addiction Medicine highlighted that while ibogaine shows promise in reducing opioid withdrawal symptoms, the evidence base is small and lacks rigorous, large-scale trials. Additionally, the review noted that ibogaine’s effects on the heart—such as the risk of QT prolongation, a condition that can lead to dangerous arrhythmias—pose serious health risks. These concerns have led many experts to warn against widespread adoption without further research.

The MAHA Movement’s push for ibogaine therapy raises ethical and practical questions about patient safety and informed consent. Because ibogaine is not FDA-approved, clinics offering it often operate in legal gray areas or outside the U.S., where regulations may be less stringent. For example, some clinics in Mexico and New Zealand provide ibogaine treatment, attracting patients who travel internationally for the therapy. However, the lack of standardized protocols for dosing, administration, and post-treatment care increases the risk of adverse outcomes. Ethicists argue that promoting ibogaine without robust evidence could mislead vulnerable individuals seeking help, potentially exposing them to harm in unregulated settings.